This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameAmrubicin
Accession NumberDB06263
TypeSmall Molecule
GroupsApproved, Investigational
Description

Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer of Amrubicin. [Press Release]

Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients
IngredientUNIICASInChI KeyDetails
Amrubicin hydrochlorideEUL6MP8FZW 110311-30-3BHMLHEQFWVQAJS-IITOGVPQSA-NDetails
ProductsNot Available
International Brands
NameCompany
CalsedNot Available
Brand mixturesNot Available
Categories
UNII93N13LB4Z2
CAS number110267-81-7
WeightAverage: 483.473
Monoisotopic: 483.152931389
Chemical FormulaC25H25NO9
InChI KeyVJZITPJGSQKZMX-XDPRQOKASA-N
InChI
InChI=1S/C25H25NO9/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31/h2-5,14-17,28-29,32-33H,6-9,26H2,1H3/t14-,15+,16-,17-,25-/m0/s1
IUPAC Name
(7S,9S)-9-acetyl-9-amino-7-{[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy}-6,11-dihydroxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
SMILES
[H][[email protected]@]1(C[[email protected]@](N)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O)O[[email protected]]1C[[email protected]](O)[[email protected]](O)CO1
Pharmacology
Indication

Investigated for use/treatment in lung cancer.

Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action

As an anthracycline, amrubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: amrubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.

TargetKindPharmacological actionActionsOrganismUniProt ID
DNA topoisomerase 2-alphaProteinunknownNot AvailableHumanP11388 details
DNANucleotideunknownNot AvailableHumannot applicabledetails
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Amrubicin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
Alendronic acidAmrubicin may increase the hypocalcemic activities of Alendronic acid.Approved
AmdinocillinThe serum concentration of Amrubicin can be decreased when it is combined with Amdinocillin.Withdrawn
AmoxicillinThe serum concentration of Amrubicin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Amrubicin.Approved, Investigational
AmpicillinThe serum concentration of Amrubicin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideHMPL-004 may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
ApocyninAcetovanillone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
Atracurium besylateAmrubicin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Amrubicin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Amrubicin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Amrubicin can be decreased when it is combined with Bacampicillin.Approved
BalsalazideBalsalazide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
BenoxaprofenBenoxaprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Amrubicin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzylpenicillinThe serum concentration of Amrubicin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Amrubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
Betulinic AcidBetulinic Acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Amrubicin.Approved, Investigational
Botulinum Toxin Type AAmrubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BAmrubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Amrubicin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Amrubicin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Amrubicin.Approved
CarbenicillinThe serum concentration of Amrubicin can be decreased when it is combined with Carbenicillin.Approved
Carbenicillin indanylThe serum concentration of Amrubicin can be decreased when it is combined with Carindacillin.Approved
CarboplatinAmrubicin may increase the ototoxic activities of Carboplatin.Approved
CarprofenCarprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved
Choline magnesium trisalicylateTrisalicylate-choline may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
Cisatracurium besylateAmrubicin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Amrubicin.Approved
Clodronic AcidAmrubicin may increase the hypocalcemic activities of Clodronate.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Amrubicin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateAmrubicin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Amrubicin can be decreased when it is combined with Cyclacillin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Amrubicin.Approved, Investigational
CyclosporineAmrubicin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
DecamethoniumAmrubicin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Amrubicin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Amrubicin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DiflunisalDiflunisal may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Amrubicin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Amrubicin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Amrubicin.Approved, Investigational
Domoic AcidAmrubicin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideAmrubicin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
E-6201E6201 may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
EbselenEbselen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
EpirizoleEpirizole may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amrubicin.Approved
EtanerceptEtanercept may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
Etidronic acidAmrubicin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
exisulindexisulind may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
FenbufenFenbufen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
FloctafenineFloctafenine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Amrubicin can be decreased when it is combined with Flucloxacillin.Approved
FlunixinFlunixin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Vet Approved
FlurbiprofenFlurbiprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Amrubicin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Amrubicin.Approved, Vet Approved
Gallamine TriethiodideAmrubicin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
HigenamineHigenamine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
IbandronateAmrubicin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Amrubicin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
IndomethacinIndomethacin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Amrubicin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
LeflunomideLeflunomide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
LornoxicamLornoxicam may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
LoxoprofenLoxoprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
LumiracoxibLumiracoxib may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Amrubicin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
MecamylamineAmrubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Amrubicin which could result in a higher serum level.Withdrawn
MeticillinThe serum concentration of Amrubicin can be decreased when it is combined with Meticillin.Approved
MetocurineAmrubicin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideAmrubicin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Amrubicin can be decreased when it is combined with Mezlocillin.Approved
MivacuriumAmrubicin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Amrubicin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved
NeosaxitoxinAmrubicin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
Niflumic AcidNiflumic Acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Amrubicin.Experimental
OlopatadineOlopatadine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Amrubicin which could result in a higher serum level.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Amrubicin.Approved
OxacillinThe serum concentration of Amrubicin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Amrubicin.Approved, Vet Approved
PamidronateAmrubicin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumAmrubicin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
PhenoxymethylpenicillinThe serum concentration of Amrubicin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
PipecuroniumAmrubicin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Amrubicin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Amrubicin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
PiroxicamPiroxicam may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
PivampicillinThe serum concentration of Amrubicin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Amrubicin can be decreased when it is combined with Pivmecillinam.Approved
Procaine benzylpenicillinThe serum concentration of Amrubicin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
PropacetamolPropacetamol may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
PTC299PTC299 may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
PyrantelAmrubicin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumAmrubicin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Amrubicin which could result in a higher serum level.Experimental, Investigational
RisedronateAmrubicin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumAmrubicin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
SeratrodastSeratrodast may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
SRT501SRT501 may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
SuccinylcholineAmrubicin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Amrubicin can be decreased when it is combined with Sulbactam.Approved
SulfasalazineSulfasalazine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Amrubicin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Withdrawn
TazobactamThe serum concentration of Amrubicin can be decreased when it is combined with Tazobactam.Approved
Technetium Tc-99m etidronateAmrubicin may increase the hypocalcemic activities of Technetium tc 99m etidronate.Approved
Technetium Tc-99m medronateAmrubicin may increase the hypocalcemic activities of Technetium Tc-99m Medronate.Approved
Tenofovir disoproxilThe serum concentration of Amrubicin can be increased when it is combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Amrubicin can be decreased when it is combined with Ticarcillin.Approved, Vet Approved
Tiludronic acidAmrubicin may increase the hypocalcemic activities of Tiludronate.Approved, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Amrubicin.Approved
TranilastTranilast may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Amrubicin.Approved, Investigational
TubocurarineAmrubicin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Amrubicin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Amrubicin.Approved
VecuroniumAmrubicin may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved
ZileutonZileuton may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidAmrubicin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Katou M, Soga N, Onishi T, Arima K, Sugimura Y: Small cell carcinoma of the prostate treated with amrubicin. Int J Clin Oncol. 2008 Apr;13(2):169-72. doi: 10.1007/s10147-007-0702-x. Epub 2008 May 8. [PubMed:18463964 ]
  2. Kurata T, Okamoto I, Tamura K, Fukuoka M: Amrubicin for non-small-cell lung cancer and small-cell lung cancer. Invest New Drugs. 2007 Oct;25(5):499-504. Epub 2007 Jul 13. [PubMed:17628745 ]
External Links
ATC CodesL01DB10 — Amrubicin
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentLung Cancers2
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)1
1, 2CompletedTreatmentMetastatic Breast Cancer (MBC)1
2Active Not RecruitingNot AvailableAdvanced thymic carcinoma / Thymic Carcinoma / Thymus Cancer1
2CompletedTreatmentExtensive-Stage Small Cell Lung Cancer1
2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)3
2CompletedTreatmentSoft Tissue Sarcoma (STS)1
2Not Yet RecruitingTreatmentSmall Cell Lung Cancer Extensive Stage1
2TerminatedTreatmentBladder Cancers1
2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2WithdrawnTreatmentMetastatic Breast Cancer (MBC)1
3Active Not RecruitingTreatmentLung Cancers1
3CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3CompletedTreatmentLung Cancers1
3TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility1.14 mg/mLALOGPS
logP1.4ALOGPS
logP1.74ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)8.1ChemAxon
pKa (Strongest Basic)7.02ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area176.61 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity122.01 m3·mol-1ChemAxon
Polarizability48.75 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tetracenequinones. These are polyaromatic hydrocarbon derivatives containing a tetracyclic cycle made up of four linearly fused benzene rings, one of which bears two ketone groups at position 1 and 4.
KingdomOrganic compounds
Super ClassBenzenoids
ClassNaphthacenes
Sub ClassTetracenequinones
Direct ParentTetracenequinones
Alternative ParentsAnthraquinones / O-glycosyl compounds / Tetralins / Aryl ketones / Aralkylamines / Oxanes / Vinylogous acids / Alpha-amino ketones / Secondary alcohols / 1,2-diols
SubstituentsTetracenequinone / 9,10-anthraquinone / 1,4-anthraquinone / Anthracene / Glycosyl compound / O-glycosyl compound / Tetralin / Aryl ketone / Aralkylamine / Oxane
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Ubiquitin binding
Specific Function:
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).
Gene Name:
TOP2A
Uniprot ID:
P11388
Uniprot Name:
DNA topoisomerase 2-alpha
Molecular Weight:
174383.88 Da
References
  1. Kurata T, Okamoto I, Tamura K, Fukuoka M: Amrubicin for non-small-cell lung cancer and small-cell lung cancer. Invest New Drugs. 2007 Oct;25(5):499-504. Epub 2007 Jul 13. [PubMed:17628745 ]
2. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
unknown
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
Drug created on March 19, 2008 10:20 / Updated on September 01, 2017 11:27